Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 65 2019-03-31
Chief Tech/Sci/R&D Officer - 2021-04-30
Corporate Officer/Principal - 2012-12-31
Director TitleAgeSince
Director/Board Member 77 1999-07-07
Director/Board Member 53 2021-05-19
Chairman 67 2023-05-28
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-.--% - - 13.55M
+0.90%+0.50%+21.25%-20.75% 62.32B
+1.66%-2.89%+59.81%+201.29% 53.94B
-1.70%+27.30%+27.30%+27.30% 38.98B
-0.74%+6.17%-53.36%-60.27% 37.89B
-1.26%-0.73%+55.22%-32.92% 29.48B
+2.79%+17.02%+135.52%-49.37% 23.55B
+0.71%+2.37%+52.50%+68.63% 20.71B
+1.53%-1.16%-1.54%+143.24% 16.71B
+4.86%+7.22%+71.09%+121.25% 16.02B
Average +0.39%+0.93%+40.87%+44.27% 33.29B
Weighted average by Cap. +0.03%+0.08%+35.42%+39.95%
Logo Mithra Pharmaceuticals S.A.
Mithra Pharmaceuticals SA is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO.
Employees
270
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!